Thus, our data suggest that the main physician expectations with regard to switching persons with T2DM to basal insulin analogues—achieving good glycemic control without hypoglycemia or weight gain—can indeed be met in routine clinical practice, outside the clinical trial setting. Here, INS is linked to type 2 diabetes mellitus.